Research programme: anti-infectives - BioAgency

Drug Profile

Research programme: anti-infectives - BioAgency

Alternative Names: NLX Target

Latest Information Update: 17 Jan 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioAgency AG
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bacterial infections; Parasitic infections

Most Recent Events

  • 20 Aug 2007 NLX Target is available for licensing (
  • 20 Aug 2007 Early research in Bacterial infections in Germany (unspecified route)
  • 20 Aug 2007 Early research in Parasitic infections in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top